Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer
1989
May mothers given warfarin breast-feed their infants?
1977
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Adenovirus infection induces amplification of persistent viral DNA sequences (simian virus 40, hepatitis B virus, bovine papillomavirus) in human and rodent cells
1990 StandoutNobel
Hepatocellular carcinoma
2018 Standout
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Mitoxantrone
1991
Ovarian cancer
2014 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Timing of debulking surgery in advanced ovarian cancer
2008
Drug penetration in solid tumours
2006 Standout
Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats
1990
Oral Anticoagulant Therapy
2012 Standout
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
1991
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
1987
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Single-Dose Toxicity Study of Hepatic Intra-arterial Infusion of Doxorubicin Coupled to a Novel Magnetically Targeted Drug Carrier
2001
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
New horizons in the extraction of bioactive compounds using deep eutectic solvents: A review
2017 Standout
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Liposome: classification, preparation, and applications
2013 Standout
Prospective Randomized Trials on Cytoreduction in Ovarian Cancer
1995
Management of Hepatocellular Carcinoma *
2005 Standout
Clinical Pharmacokinetics of Doxorubicin
1988
Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy
2010 Standout
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
1989
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Inhibition of N‐methyl‐N′'‐nitro‐n‐nitrosoguanidine‐induced methotrexate and adriamycin resistance in CHO cells by adeno‐associated virus type 2
1990 StandoutNobel
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
2004
Physiological pharmacokinetie model of adriamycin delivered via magnetic albumin microspheres in the rat
1989
Tocotrienols in health and disease: The other half of the natural vitamin E family
2007
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Prognostic Factors in Patients With Hepatocellular Carcinoma Receiving Systemic Chemotherapy
1992
Chronic hepatitis B
2007 Standout
Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
1989
Doxorubicin clearance in the obese.
1988
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)
1994
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients
1998
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Dissociation of carcinogen-induced SV40 DNA-Amplification and amplification of AAV DNA in a Chinese hamster cell line
1988 StandoutNobel
Idarubicin
1991
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
Antibody-targeted polymer-bound drugs
1995
Nonresectional therapies for hepatocellular carcinoma
1997
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Hepatocellular carcinoma
2022 Standout
The dawning era of polymer therapeutics
2003 Standout
Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
2006
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Cancer of the Ovary
2004 Standout
Selective dna‐amplification induced by carcinogens (initiators): Evidence for a role of proteases and DNA polymerase alpha
1985 StandoutNobel
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
1983
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
2005
Gene amplification, drug resistance, and cancer.
1984
Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations
1994
Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients
1985 Standout
Clinical Pharmacokinetics of Oral Anticoagulants
1979
Applications of magnetic nanoparticles in biomedicine
2003 Standout
Warfarin STEREOCHEMICAL ASPECTS OF ITS METABOLISM AND THE INTERACTION WITH PHENYLBUTAZONE
1974
Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug
1986
Pharmacokinetics of the enantiomers of acenocoumarol in man.
1981
Cancer, Clinical Pharmacology, and Aging
1987
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
2016
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.
1979
Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus
1986 StandoutNobel
Hepatocellular carcinoma
2000
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The Anthracycline Antineoplastic Drugs
1981 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Systemic chemotherapy for hepatocellular carcinoma
1992
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs
1982
Works of Chan Kk being referenced
Survival after negative second-look laparotomy.
1989
Rapid analytic method for adriamycin and metabolites in human plasma by a thin-film fluorescence scanner.
1976
Second-look laparotomy in the management of epithelial ovarian carcinoma: an evaluation of fifty cases.
1984
Combination of bleomycin and mitomycin after failure of cisplatin and alkylating agent therapy in epithelial ovarian cancer.
1986
A fluorometric determination of adriamycin and its metabolites in biological tissues.
1973
Effects of tocotrienols on cell viability and apoptosis in normal murine liver cells (BNL CL.2) and liver cancer cells (BNL 1ME A.7R.1), in vitro.
2005
Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.
1978
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
1984
Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer.
1989
Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols.
1973
Metabolism of methotrexate in man after high and conventional doses.
1980